brand logo

Am Fam Physician. 2022;106(5):582-583

Author disclosure: No relevant financial relationships.

Vericiguat (Verquvo) is labeled for the treatment of adults with symptomatic chronic heart failure (HF) and an ejection fraction of less than 45%. It is used to reduce the composite risk of cardiovascular death and HF-related hospitalization following a previous hospitalization for HF or the need for outpatient intravenous diuretics.1 Vericiguat causes smooth muscle relaxation and vasodilation by stimulating soluble guanylate cyclase (which is decreased in HF), both independently and synergistically with nitric oxide, a unique mechanism.

DrugDosageDose formCost of full course*
Vericiguat (Verquvo)Initial dosage of 2.5 mg once daily with food, then doubled every two weeks to reach target dosage of 10 mg daily, as toleratedTablets: 2.5mg; 5 mg; 10 mg$640
Already a member/subscriber?  Log In

Subscribe

From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.